Status:
COMPLETED
Effect of Tiotropium on Inflammation and Exacerbations in COPD
Lead Sponsor:
Royal Free and University College Medical School
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Patients with COPD experience exacerbations that are a major cause of morbidity. Exacerbations are associated with increased airway and systemic inflammation and those experiencing frequent exacerbati...
Detailed Description
Patients with COPD will be randomised to tiotropium or placebo in addition to their usual medication. They will be followed prospectively over 1 year and provide sputum for quantification of IL-6 and ...
Eligibility Criteria
Inclusion
- diagnosis of COPD,
- FEV1 \< 80% predicted,
- minimum 10 pack year smoking history
Exclusion
- asthma,
- atopic disease,
- eosinophilia,
- history of malignancy,
- history of clinically significant pulmonary disease
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00405236
Start Date
October 1 2002
End Date
January 1 2005
Last Update
November 29 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Chest Hospital
London, United Kingdom